FICHIT

Je m'inscris

ABILITY PHARMACEUTICALS

0/5 (0 note(s))
Note donnée : aucune
Madrid
0
Develops safer human therapeutics to treat cancer and other indications with unmet medical needs characterized by blockbuster potential, lower risk of drug development failure and lower development costs (fast track review), very high pricing with low cost of goods and low promotional costs in few specialized physicians and centers.
ABTL0812 is currently finalizing a phase I/Ib, first in humans, clinical trial conducted at Hospital Clinic Barcelona and Institut Català d'Oncologia. The trial includes up to 27 patients with advanced solid tumors. ABTL0812 is confirming its predicted high safety profile and pharmacokinetic properties compatible with once daily oral administration. Several disease stabilizations have been observed to date and biomarkers are showing inhibition of the Akt/mTOR pathway.
ABTL0812 is an inhibitor of the Akt/mTORC signaling pathway with a novel mechanism of action fully differentiated from other PI3K/Akt/mTOR under development or marketed. Cell death is mediated by autophagy.
DOMENECH Carles
www.abilitypharma.com
Private Equity

Fiche créée le 10/04/2016 par Guillaume   vue 8 fois.